Liquidia Corp (LQDA) shareholders
Close on Nov 17, 2026Market cap $5.08BP/E 40.8Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 10,551,901 | 11.90% | 13G (passive) amendment | Jun 30, 2026 |
| Short Daniel S. Joint filing with Wehrly, Mark C. (9.90%), Saito Edric C. (9.90%) and 15 more | 8,656,038 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Dapice Joshua J. Joint filing with Wehrly, Mark C. (9.95%), Short Daniel S. (9.95%) and 17 more | 8,565,638 | 9.95% | 13G (passive) amendment | Sep 30, 2025 |
| Spokes, Andrew J. M. Joint filing with Farallon Capital Management, L.L.C. (9.40%), Dapice Joshua J. (9.40%) and 13 more | 8,365,038 | 9.40% | 13G (passive) amendment | Jun 30, 2026 |
| Caligan Partners LP Joint filing with David Johnson (9.80%) | 8,118,592 | 9.60% | 13D (active) amendment | Sep 10, 2024 |
| Warren, John R. Joint filing with Wehrly, Mark C. (8.00%), Dapice Joshua J. (8.00%) and 15 more | 6,832,472 | 8.00% | 13G (passive) | Jul 7, 2025 |
| Paul B Manning | 4,946,771 | 6.50% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LQDA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,788,586 | 12.05% | $860.17M | +5,299,442 | 0.01% |
| Farallon Capital Management LLC | 8,365,038 | 9.35% | $666.94M | −291,000 | 3.08% |
| Caligan Partners LP | 8,118,892 | 9.07% | $647.32M | – | 30.45% |
| Findell Capital Management LLC | 3,502,112 | 3.91% | $279.22M | – | 39.31% |
| Vanguard Capital Management LLC | 3,139,183 | 3.51% | $250.29M | +212,238 | 0.01% |
| State Street Corp | 3,030,395 | 3.39% | $241.61M | +1,148,796 | 0.01% |
| Opaleye Management Inc. | 2,447,500 | 2.73% | $195.14M | −97,500 | 17.67% |
| Geode Capital Management, LLC | 2,121,290 | 2.37% | $169.16M | +192,321 | 0.01% |
| Bank Of America Corp /De/ | 1,991,566 | 2.22% | $158.79M | −296,226 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,940,364 | 2.17% | $154.71M | +987,213 | 0.02% |
| Vanguard Portfolio Management LLC | 1,532,151 | 1.71% | $122.16M | +899,526 | 0.01% |
| Caprock Group, LLC | 1,409,759 | 1.57% | $112.40M | +42,524 | 2.15% |
| Mpm Bioimpact LLC | 1,386,174 | 1.55% | $110.52M | −18,984 | 6.74% |
| D. E. Shaw & Co., Inc. | 1,267,706 | 1.42% | $101.07M | +394,641 | 0.05% |
| Fuller & Thaler Asset Management, Inc. | 1,209,604 | 1.35% | $96.44M | New | 0.26% |
| Goldman Sachs Group Inc | 958,892 | 1.07% | $76.45M | +146,902 | 0.01% |
| Federated Hermes, Inc. | 816,187 | 0.91% | $65.07M | +377,420 | 0.09% |
| Northern Trust Corp | 709,063 | 0.79% | $56.53M | +129,188 | 0.01% |
| Charles Schwab Investment Management Inc | 674,033 | 0.75% | $53.74M | +116,833 | 0.01% |
| Morgan Stanley | 658,441 | 0.74% | $52.50M | +313,770 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 336 | 73M | 81.1% | 129 / 103 | 80 / 33 | 17M | 6M |
| Q1 2026 | 244 | 62M | 68.8% | 55 / 77 | 78 / 36 | 11M | 8M |
| Q4 2025 | 227 | 62M | 69.1% | 61 / 70 | 72 / 33 | 8M | 11M |
| Q3 2025 | 199 | 65M | 72.2% | 52 / 65 | 59 / 30 | 19M | 12M |
| Q2 2025 | 177 | 58M | 64.3% | 37 / 64 | 57 / 27 | 10M | 8M |
| Q1 2025 | 168 | 55M | 61.7% | 28 / 65 | 50 / 22 | 10M | 6M |
| Q4 2024 | 164 | 52M | 57.6% | 31 / 68 | 38 / 19 | 7M | 9M |
| Q3 2024 | 154 | 53M | 59.0% | 36 / 51 | 45 / 17 | 15M | 4M |
| Q2 2024 | 137 | 46M | 51.9% | 29 / 59 | 32 / 29 | 5M | 6M |
| Q1 2024 | 139 | 48M | 53.2% | 43 / 45 | 36 / 19 | 15M | 4M |
| Q4 2023 | 116 | 37M | 41.0% | 30 / 43 | 31 / 16 | 11M | 3M |
| Q3 2023 | 102 | 29M | 31.9% | 18 / 31 | 34 / 18 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
231 funds held LQDA in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LQDA | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4,232,422 | 4.73% | $337.45M | 0.30% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,259,289 | 2.52% | $180.13M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,811,474 | 2.02% | $144.43M | 0.17% | Jun 30, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 812,800 | 0.91% | $64.80M | 1.05% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 805,880 | 0.90% | $64.25M | 0.07% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 771,365 | 0.86% | $64.88M | 0.19% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 651,493 | 0.73% | $51.94M | 0.34% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 643,837 | 0.72% | $51.33M | 0.30% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 631,318 | 0.71% | $50.33M | 0.61% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 521,706 | 0.58% | $41.60M | 0.28% | Jun 30, 2026 |
| Small Cap Growth Fund | 413,511 | 0.46% | $34.78M | 0.62% | Jul 31, 2026 |
| State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF | 398,580 | 0.45% | $31.78M | 0.61% | Jun 30, 2026 |
| Oberweis Micro-Cap Fund | 392,100 | 0.44% | $31.26M | 1.94% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 388,092 | 0.43% | $30.94M | 0.27% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 364,952 | 0.41% | $29.10M | 0.24% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Roger Jeffs | Chief Executive Officer, Director | 2,167,515 | 2.42% | Oct 13, 2026 |
| Jason Adair | Chief Business Officer | 177,269 | 0.20% | Oct 28, 2026 |
| Dana Boyle | Chief Accounting Officer | 164,028 | 0.18% | Oct 28, 2026 |
| Russell Schundler | General Counsel | 617,341 | 0.69% | Oct 13, 2026 |
| Rajeev Saggar | Chief Medical Officer | 141,467 | 0.16% | Oct 13, 2026 |
| Michael Kaseta | CFO and COO | 340,148 | 0.38% | Oct 13, 2026 |
| Sanjeev Khindri | Chief Development Officer | 64,846 | 0.07% | Oct 13, 2026 |
| Sarah Krepp | Chief Human Resource Officer | 115,241 | 0.13% | Oct 13, 2026 |
| Scott Moomaw | Chief Commercial Officer | 181,487 | 0.20% | Oct 13, 2026 |
| Stephen M. Bloch | Director | 104,570 | 0.12% | Oct 7, 2026 |
| Raman Singh | Director | 53,105 | 0.06% | Sep 15, 2026 |
| Katherine Rielly-Gauvin | Director | 56,364 | 0.06% | Aug 21, 2026 |
| Arthur S. Kirsch | Director | 46,637 | 0.05% | Jun 18, 2026 |
| Paul B. Manning | Director | 673,878 | 0.75% | Jun 18, 2026 |
| Partners LP Caligan | Director, 10% owner | 8,163,229 | 9.12% | Jun 18, 2026 |
| Joanna Horobin | Director | 39,637 | 0.04% | Jun 18, 2026 |
| Damian deGoa | Director | 92,353 | 0.10% | Jun 18, 2026 |
| David Edward Johnson | Director, 10% owner | 8,157,347 | 9.11% | Jun 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dana Boyle Chief Accounting Officer | Oct 26, 2026 | Sale(10b5-1 plan) | −1,581 | $43.19 | $68.28K | 164,028 |
| Jason Adair Chief Business Officer | Oct 26, 2026 | Sale(10b5-1 plan) | −688 | $43.19 | $29.71K | 177,269 |
| Russell Schundler General Counsel | Oct 12, 2026 | Sale(10b5-1 plan) | −13,692 | $28.48 | $389.95K | 602,841 |
| Rajeev Saggar Chief Medical Officer | Oct 12, 2026 | Sale(10b5-1 plan) | −9,218 | $28.48 | $262.53K | 126,368 |
| Scott Moomaw Chief Commercial Officer | Oct 12, 2026 | Sale(10b5-1 plan) | −8,863 | $28.48 | $252.42K | 181,487 |
| Sarah Krepp Chief Human Resource Officer | Oct 12, 2026 | Sale(10b5-1 plan) | −5,245 | $28.48 | $149.38K | 115,241 |
| Sanjeev Khindri Chief Development Officer | Oct 12, 2026 | Sale(10b5-1 plan) | −1,101 | $28.48 | $31.36K | 64,846 |
| Michael Kaseta CFO and COO | Oct 12, 2026 | Sale(10b5-1 plan) | −18,938 | $28.48 | $539.35K | 340,148 |
| Roger Jeffs Chief Executive Officer, Director | Oct 12, 2026 | Sale(10b5-1 plan) | −32,744 | $28.48 | $932.55K | 1,125,848 |
| Dana Boyle Chief Accounting Officer | Oct 12, 2026 | Sale(10b5-1 plan) | −5,892 | $28.48 | $167.80K | 165,609 |
| Jason Adair Chief Business Officer | Oct 12, 2026 | Sale(10b5-1 plan) | −7,301 | $28.48 | $207.93K | 177,957 |
| Russell Schundler General Counsel | Oct 9, 2026 | Option exercise | +6,409 | – | – | 616,533 |
| Russell Schundler General Counsel | Oct 9, 2026 | Option exercise | +3,758 | – | – | 610,124 |
| Rajeev Saggar Chief Medical Officer | Oct 9, 2026 | Option exercise | +4,486 | – | – | 135,586 |
| Rajeev Saggar Chief Medical Officer | Oct 9, 2026 | Option exercise | +3,530 | – | – | 131,100 |
| Scott Moomaw Chief Commercial Officer | Oct 9, 2026 | Option exercise | +4,358 | – | – | 190,350 |
| Scott Moomaw Chief Commercial Officer | Oct 9, 2026 | Option exercise | +3,108 | – | – | 185,992 |
| Sarah Krepp Chief Human Resource Officer | Oct 9, 2026 | Option exercise | +3,178 | – | – | 120,486 |
| Michael Kaseta CFO and COO | Oct 9, 2026 | Option exercise | +7,049 | – | – | 359,086 |
| Michael Kaseta CFO and COO | Oct 9, 2026 | Option exercise | +5,828 | – | – | 352,037 |
| Roger Jeffs Chief Executive Officer, Director | Oct 9, 2026 | Option exercise | +14,333 | – | – | 1,158,592 |
| Roger Jeffs Chief Executive Officer, Director | Oct 9, 2026 | Option exercise | +13,833 | – | – | 1,144,259 |
| Dana Boyle Chief Accounting Officer | Oct 9, 2026 | Option exercise | +3,178 | – | – | 171,501 |
| Jason Adair Chief Business Officer | Oct 9, 2026 | Option exercise | +3,868 | – | – | 185,258 |
| Jason Adair Chief Business Officer | Oct 9, 2026 | Option exercise | +2,474 | – | – | 181,390 |
| Jason Adair Chief Business Officer | Oct 9, 2026 | Option exercise | +3,906 | – | – | 178,916 |
| Stephen M. Bloch Director | Oct 5, 2026 | Sale | −235,477 | $27.13 | $6.39M | 0 |
| Raman Singh Director | Sep 14, 2026 | Option exercise | +8,468 | $9.31 | $78.84K | 53,105 |
| Raman Singh Director | Sep 14, 2026 | Sale | −8,468 | $66.16 | $560.24K | 44,637 |
| Raman Singh Director | Sep 11, 2026 | Option exercise | +556 | $8.63 | $4.80K | 45,193 |
| Raman Singh Director | Sep 11, 2026 | Option exercise | +8,468 | $9.31 | $78.84K | 53,661 |
| Raman Singh Director | Sep 11, 2026 | Sale | −9,024 | $68.62 | $619.23K | 44,637 |
| Sarah Krepp Chief Human Resource Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −274 | $67.76 | $18.57K | 117,308 |
| Jason Adair Chief Business Officer | Aug 21, 2026 | Option exercise | +9,000 | $9.31 | $83.79K | 225,438 |
| Jason Adair Chief Business Officer | Aug 21, 2026 | Option exercise | +11,799 | $9.31 | $109.85K | 237,237 |
| Jason Adair Chief Business Officer | Aug 21, 2026 | Option exercise | +10,762 | $14.20 | $152.82K | 247,999 |
| Jason Adair Chief Business Officer | Aug 21, 2026 | Option exercise | +238 | $14.20 | $3.38K | 248,237 |
| Jason Adair Chief Business Officer | Aug 21, 2026 | Sale(10b5-1 plan) | −31,799 | $69.09 | $2.20M | 216,438 |
| Jason Adair Chief Business Officer | Aug 21, 2026 | Sale(10b5-1 plan) | −41,832 | $69.09 | $2.89M | 174,606 |
| Katherine Rielly-Gauvin Director | Aug 20, 2026 | Option exercise | +11,727 | $2.51 | $29.43K | 56,364 |
| Katherine Rielly-Gauvin Director | Aug 20, 2026 | Option exercise | +6,666 | $2.59 | $17.26K | 63,030 |
| Katherine Rielly-Gauvin Director | Aug 20, 2026 | Sale(10b5-1 plan) | −18,393 | $72.23 | $1.33M | 44,637 |
| Katherine Rielly-Gauvin Director | Aug 19, 2026 | Option exercise | +23,455 | $2.51 | $58.87K | 68,092 |
| Katherine Rielly-Gauvin Director | Aug 19, 2026 | Sale(10b5-1 plan) | −36,789 | $74.99 | $2.76M | 44,637 |
| Katherine Rielly-Gauvin Director | Aug 19, 2026 | Option exercise | +13,334 | $2.59 | $34.54K | 81,426 |
| Rajeev Saggar Chief Medical Officer | Aug 19, 2026 | Option exercise | +50,000 | $3.73 | $186.50K | 192,265 |
| Rajeev Saggar Chief Medical Officer | Aug 19, 2026 | Sale | −50,000 | $74.06 | $3.70M | 142,265 |
| Rajeev Saggar Chief Medical Officer | Aug 17, 2026 | Sale | −29,534 | $76.84 | $2.27M | 142,265 |
| Jason Adair Chief Business Officer | Jul 27, 2026 | Sale(10b5-1 plan) | −688 | $87.53 | $60.22K | 216,438 |
| Dana Boyle Chief Accounting Officer | Jul 27, 2026 | Sale(10b5-1 plan) | −1,600 | $87.53 | $140.05K | 167,919 |
| Stephen M. Bloch Director | Jul 23, 2026 | Sale | −96,400 | $89.44 | $8.62M | 505,077 |
| Stephen M. Bloch Director | Jul 23, 2026 | Sale | −3,600 | $90.71 | $326.56K | 501,477 |
| Stephen M. Bloch Director | Jul 22, 2026 | Sale | −14,562 | $89.24 | $1.30M | 601,477 |
| Stephen M. Bloch Director | Jul 22, 2026 | Sale | −48,032 | $88.65 | $4.26M | 616,039 |
| Stephen M. Bloch Director | Jul 22, 2026 | Sale | −37,406 | $87.70 | $3.28M | 664,071 |
| Stephen M. Bloch Director | Jul 21, 2026 | Sale | −74,444 | $79.98 | $5.95M | 702,033 |
| Stephen M. Bloch Director | Jul 21, 2026 | Sale | −556 | $80.66 | $44.85K | 701,477 |
| Stephen M. Bloch Director | Jul 20, 2026 | Sale | −3,596 | $79.55 | $286.06K | 776,477 |
| Scott Moomaw Chief Commercial Officer | Jul 13, 2026 | Sale(10b5-1 plan) | −8,864 | $71.52 | $633.95K | 182,485 |
| Scott Moomaw Chief Commercial Officer | Jul 13, 2026 | Sale(10b5-1 plan) | −675 | $71.39 | $48.19K | 191,349 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Liquidia's stock actually held short. Settlement fails (shares not delivered on time) peaked at 29,000 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ramandeep Singh Director | Sep 14, 2026 | 8,468 | $560.24K | Sep 14, 2026 | Stock Option Exercise |
| Ramandeep Singh Director | Sep 11, 2026 | 9,024 | $619.21K | Sep 11, 2026 | Stock Option Exercise |
| Jason Adair Officer | Aug 21, 2026 | 73,631 | $5.23M | Aug 21, 2026 | Exercise of Stock Options |
| Katherine Rielly-Gauvin Director | Aug 19, 2026 | 55,182 | $4.10M | Aug 19, 2026 | Exercise of Stock Options |
| Rajeev Saggar Officer | Aug 19, 2026 | 50,000 | $3.70M | Aug 19, 2026 | Stock Option Exercise |
| Rajeev Saggar Officer | Aug 17, 2026 | 29,534 | $2.27M | Aug 17, 2026 | Performance Shares |
| Sarah Krepp Officer | Jun 11, 2026 | 24,880 | $1.62M | Jun 11, 2026 | Employee Stock Purchase Plan |
| Canaan VIII LP Director | Jun 10, 2026 | 200,000 | $13.00M | Jun 10, 2026 | pre-IPO investment |
| Canaan VIII LP Director | Jun 8, 2026 | 200,000 | $12.80M | Jun 8, 2026 | pre-IPO investment |
| Canaan VIII LP Director | Jun 4, 2026 | 200,000 | $13.00M | Jun 4, 2026 | Pre-IPO Investment |
| Paul B. Manning Director | Jun 4, 2026 | 200,000 | $11.14M | Jun 4, 2026 | Registered Direct Offering |
| Arthur S. Kirsch Director | Jun 1, 2026 | 30,000 | $1.84M | Jun 1, 2026 | Market Purchase |
| Ramandeep Singh Director | May 21, 2026 | 29,494 | $1.77M | May 21, 2026 | Stock Option Exercise |
| Serendipity Biopharma LLC Director, Officer | May 20, 2026 | 106,428 | $6.38M | May 20, 2026 | Merger or Acquisition |
| Serendipity Biopharma LLC Director, Officer | May 14, 2026 | 100,000 | $5.76M | May 14, 2026 | Merger or Acquisition |
See a number that looks wrong?